文献速递血脂与心血管预防冠心病

老年人群长期使用依洛尤单抗的降脂获益

Long-Term Lipid Lowering With Evolocumab in Older Individuals.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

基于FOURIER及其开放标签延展研究,评估≥75岁动脉粥样硬化性心血管病患者长期使用依洛尤单抗的获益与安全性。结果显示,老年患者主要终点风险降低至少不劣于年轻患者,绝对风险降低更明显,NNT更小,安全性事件发生率总体相似。

要点

  • ≥75岁患者早期启用依洛尤单抗,主要终点HR 0.79(95%CI 0.64-0.97)。
  • 老年患者绝对风险降低5.4%,NNT为19,优于年轻患者的2.3%和44。
  • 两个年龄组安全性事件年化发生率总体相似,无显著安全担忧。

核心结论

  • ≥75岁动脉粥样硬化性心血管病患者早期启动长期依洛尤单抗治疗,心血管获益至少不劣于年轻患者。
  • 老年患者绝对风险降低更明显、NNT更小,且无显著安全性担忧。

研究设计与样本

  • FOURIER随机对照试验纳入27,564例18至85岁动脉粥样硬化性心血管病患者,随机接受依洛尤单抗或安慰剂,中位随访2.2年。
  • FOURIER-OLE开放标签延展研究中6,635例参与者转为开放标签依洛尤单抗,额外中位随访5年。
  • FOURIER与FOURIER-OLE合计中位随访7.1年(Q1-Q3 6.7-7.6年),最长8.7年。

主要发现

  • 27,564例中2,526例(9%)入组FOURIER时≥75岁,中位年龄77岁(Q1-Q3 76-79岁)。
  • 早期启用依洛尤单抗降低主要终点:老年患者HR 0.79(95%CI 0.64-0.97),年轻患者HR 0.86(95%CI 0.80-0.92),P交互=0.43。
  • 绝对风险降低在老年患者为5.4%(95%CI -2.0%至12.8%),年轻患者为2.3%(95%CI 0.1%-4.5%),NNT分别为19和44。
  • 两个年龄组各治疗臂的安全性事件年化发生率总体相似。

临床怎么用

  • 对≥75岁动脉粥样硬化性心血管病患者,可考虑早期启动依洛尤单抗以降低复合心血管终点风险。
  • 老年患者绝对获益更大、NNT更低,支持在老年人群中进行强化降脂治疗。

局限性

  • 分析对复合终点各单项事件把握度不足。
  • FOURIER-OLE为开放标签延展研究,非随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concerns about the efficacy and safety of intensive low-density lipoprotein cholesterol lowering in older patients have led to weaker recommendations in the U.S. guidelines for patients ≥75 years of age compared to younger patients. Data are sparse on long-term benefits of proprotein convertase subtilisin/kexin type 9 inhibition in older patients. OBJECTIVES: This study aims to assess the long-term benefit of evolocumab among patients aged ≥75 years. METHODS: The FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial randomized 27,564 patients who were 18 to 85 years of age with atherosclerotic cardiovascular disease to evolocumab vs placebo with 2.2 years of median follow-up. In the open-label extension (FOURIER-OLE), 6,635 participants were transitioned to open-label evolocumab for an additional 5-year median follow-up. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) was compared based on the original allocation to evolocumab vs placebo stratified by age (<75 vs ≥75 years). Analyses were underpowered for individual components of the composite endpoint. The annualized incidence rates for adverse events of interest were calculated for the OLE population across age groups during the parent FOURIER trial by randomized treatment arm and during the combined parent and FOURIER-OLE studies for patients originally allocated to evolocumab. RESULTS: Of 27,564 patients, 2,526 (9%) were ≥75 years of age at entry into FOURIER (median age: 77 years [Q1-Q3: 76-79 years]). The median follow-up in FOURIER and FOURIER-OLE was 7.1 years (Q1-Q3: 6.7-7.6 years), with a maximum of 8.7 years. Earlier initiation of evolocumab reduced the rate of the primary endpoint at least as well in older (HR: 0.79; 95% CI: 0.64-0.97) as in younger patients (HR: 0.86; 95% CI: 0.80-0.92; P interaction = 0.43). The absolute risk reductions were 5.4% (95% CI: -2.0% to 12.8%) in older and 2.3% (95% CI: 0.1%-4.5%) in younger patients, leading to numbers needed to treat of 19 and 44, respectively. The annualized incidence rates of safety events generally appeared similar across treatment arms in both age groups. CONCLUSIONS: Early initiation of long-term evolocumab provides older patients with atherosclerotic cardiovascular disease cardiovascular benefits at least as good as those observed in younger patients, with a more favorable number needed to treat in older patients for reducing a composite endpoint and no significant safety concerns. These findings may be helpful in guiding future recommendations.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Al Said S, O'Donoghue ML, Ran X, et al. Long-Term Lipid Lowering With Evolocumab in Older Individuals. J Am Coll Cardiol. 2025. PMID: 39909681. doi:10.1016/j.jacc.2024.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。